VectivBio Announces Pricing of $125 Million Underwritten

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company...

Related Keywords

Minnesota ,United States ,New York ,Boston ,Massachusetts ,Switzerland ,Marshall Wace ,Patrick Malloy ,Piper Sandler ,Forbion Growth Opportunities Fund ,Exchange Commission ,Exchange Commission On Form ,Strategic Communications ,Prospectus Department ,Eventide Asset Management ,Equity Syndicate Prospectus Department ,Piper Sandler Co ,Syndicate Department ,Vectivbio Holding Ag Nasdaq ,Frazier Life Sciences ,Cowen Healthcare Investments ,Driehaus Capital Management ,Growth Opportunities Fund ,Surveyor Capital ,Venrock Healthcare Capital Partners ,Vivo Capital ,Acute Graft Versus Host Disease ,Inherited Metabolic Diseases ,Risk Factor ,Registration Statement ,Annual Report ,Bio Contacts ,Investor Relations ,Nasdaq Vect ,Ectivbio Ag ,